A team from Clínic-IDIBAPS has introduced a modification to a CAR-T immunotherapy for multiple myeloma that makes it more durable, according to resul1
The Committee for the Evaluation of Medicinal Products for Human Use of the Spanish Agency of Medicines and Medical Devices (AEMPS) has approved ARI01
A study published recently in the journal Clinical Cancer Research identified biomarkers that can predict the response to CAR T-cell therapy targetin1
An international team, co-led by the Hospital Clínic-IDIBAPS, has identified four biomarkers that determine the risk of the recurrence of this cancer1
The ”la Caixa” Foundation will allocate 4.6 million euros to promoting research at the Hospital Clínic Barcelona, in order to develop new, personaliz1
A multicentre study led by the Hospital Clínic Barcelona-IDIBAPS demonstrates the efficacy of the CAR T-cell therapy ARI0002h in treating patients wi1
The Hospital Clínic-IDIBAPS has developed the first CAR T-cell therapy in Europe to treat multiple myeloma, the second most common type of blood canc1
On Thursday, 11 November, the Spanish Cancer Association (AECC) awarded the AECC 2021 Grants for Cancer Research at an event held at the organization1
People who have a haematological disease, such as lymphoma or leukaemia, present a state of immunosuppression caused both by the illness itself and t1
In recent years, one of the strategies developed in the field of haematology is the modification of the patient’s immune system, also known as ‘immun1
